Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2023-06-12 00:00:00 ET · period of report 2023-06-08 · accession 0001209191-23-036529 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-12 | 2023-06-08 | ACAD | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $25.02 | -974 | 22.8K | -4% | -$24.4K |
| D | 2023-06-12 | 2023-06-08 | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | $0.00 | +1,893 | 23.8K | +9% | $0 |
| D | 2023-06-12 | 2023-06-08 | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | $0.00 | -1,893 | 1,893 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-08 | S | D | 974 | $25.02 | 22,824 | D | — | — | |
| 2 | Common | Common Stock | 2023-06-08 | M | A | 1,893 | $0.00 | 23,798 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2023-06-08 | M | D | 1,893 | $0.00 | 1,893 | D | — · — to — | 1,893 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. (F3) The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024. |